Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
3577- CUR,    Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
- Trial, AD, NA
*cognitive∅, *BioAv↑,
6238- CUSP9,    A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
- Trial, GBM, NA
toxicity↓, TrxR↓, ROS↓, TumCI↓, TumCMig↓, TumCA↓, MMP2↓, MMP9↓, COX2↓, ALDH↓, TumAuto↑, P-gp↓, eff↑,
6241- CUSP9,    RECURRENT GLIOBLASTOMA: INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4
- Trial, GBM, NA
eff↑,
6262- Cyste,    A Randomized Controlled Crossover Trial with Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on White Blood Cell Cystine Levels and Comparison of Safety
- Trial, Nor, NA
*eff↑,
6260- Cyste,    A novel sustained‐release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
- Trial, Nor, NA
*toxicity?,
6592- DAS,    Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- Trial, CML, NA
Dose↝, other↝, OS↑,
6679- DCA,    GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial
- Trial, Melanoma, NA
PDK1↓, Half-Life↝, eff↑, NP/CIPN↑, Dose↝, Half-Life↝,
6678- DCA,  Cisplatin,    Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma
- Trial, HNSCC, NA
PDK1↓, OS∅, lactateProd↓, toxicity↝, FAO↑,
6749- DHA,    The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial
- Trial, BC, NA
*IFN-γ↑, *TNF-α↑, Imm↑,
6750- DHA,  Chemo,    Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial
- Trial, BC, NA
*CD14↑, *NLR↓, eff↑, *IL4↑, *IL10↑, *IFN-γ↑, *TNF-α↑, Imm↑, eff↑, TumW↓,
6751- DHA,    Exploratory outcomes of the DHA WIN randomized controlled trial: Supplementing women with docosahexaenoic acid did not reduce the impact of neoadjuvant breast cancer chemotherapy on quality of life or exercise behaviour
- Trial, BC, NA
QoL∅,
6752- DHA,    A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
- Trial, BC, NA
TNF-α∅, IL1β∅, COX2∅,
6754- DHA,    Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
- Trial, AD, NA
*DHA↑, *eff↝, *BrainVol∅, *cognitive∅,
6755- DHA,    Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia
- Trial, AD, NA
*other↝,
6758- DHA,  Chemo,    Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial
- Trial, BC, NA
ChemoSen↑, selectivity↑, ROS↑, *toxicity↓, Dose↝,
6760- DHA,    Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans
- Trial, Nor, NA
*BP↓, *eff↝,
6761- DHA,    Docosahexaenoic acid reduces resting blood pressure but increases muscle sympathetic outflow compared with eicosapentaenoic acid in healthy men and women
- Trial, Nor, NA
*BP↓,
6711- dietF,    Gut-microbiota-targeted diets modulate human immune status
- Trial, Nor, NA
*GutMicro↑, *Inflam↓, *Imm↑, *Obesity↓, *AntiDiabetic↑, *AntiCan↑, *cardioP↑, *IL6↓, *IL10↓, *IL12↓,
1848- dietFMD,  Chemo,    Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
- Trial, BC, NA
ChemoSideEff↓, ChemoSen↑, eff↑,
1855- dietFMD,    Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study
- Trial, NA, NA
ChemoSideEff↓, QoL↑, IGF-1↓, Insulin↓,
1862- dietFMD,    Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial
- Trial, Var, NA
OS↑,
1842- dietFMD,    Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment
- Trial, Var, NA
Strength∅, Weight∅, IGF-1↓, IGFBP3↑, IGFBP1↑, eff↑,
1841- dietFMD,    Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
- Trial, Var, NA
BG↓, AntiCan↑, IFN-γ↑, eff↑, Dose↝, CD14↓, IGF-1↓, IGFR↓, CD8+↑, NK cell↑,
5193- dietMet,  Rad,    A Phase I Trial of a Methionine Restricted Diet with Concurrent Radiation Therapy
- Trial, Var, NA
toxicity↝, other↝,
2165- dietP,  SFN,    Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study
- Trial, PC, NA
Dose↝, OS↑, eff↝,
2160- dietP,    Dietary proteins and protein sources and risk of death: the Kuopio Ischaemic Heart Disease Risk Factor Study
- Trial, Heart, NA
Risk↓,
2154- dietP,  Ex,    American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)
- Trial, Colon, NA
OS↑,
6729- Dipy,    Dipyridamole prevents triple-negative breast-cancer progression
- Trial, BC, MDA-MB-231
TumCG↓, TumMeta↑, β-catenin/ZEB1↓, *AntiAg↑, TumCCA↑, Wnt↓, NF-kB↓,
6737- Dipy,    Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19 (TOLD)
- Trial, Nor, NA
*AntiAg↑, *Inflam↓, *AntiThr↑, *Dose↝,
6265- DL,    Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee
- Trial, Var, NA
toxicity↓, Dose↑, OS↑,
6266- DL,    Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer
- Trial, BC, NA
chemoPv↑, cycD1/CCND1↓, IGF-1↑, TumCCA↑, TumCP↓,
6279- DL,    Human breast tissue disposition and bioactivity of limonene in women with early stage breast cancer
- Trial, BC, NA
chemoPv↑, cycD1/CCND1↓,
4917- DSF,  Chemo,  Cu,    Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma
- Trial, GBM, NA
OS∅, toxicity↑,
6803- EA,    Effects of Ellagic Acid on Oxidative Stress Index, Inflammatory Markers and Quality of Life in Patients With Irritable Bowel Syndrome: Randomized Double-blind Clinical Trial
- Trial, IBD, NA
*Dose↝, *MDA↓, *TAC↑, *CRP↓, *IL6↓, *Inflam↓, *ROS↓, *QoL↑, *toxicity↓,
6612- Ech,    Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial
- Trial, Nor, NA
*Imm↑, Dose↝, eff↑,
6603- Ech,  doxoR,    The effect of Echinacea purpurea on the pharmacokinetics of docetaxel
- Trial, Var, NA
other∅, other↝, Imm↑, CYP3A4⇅, other↑,
7225- EGb 761,    Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial
- Trial, AD, NA
*cognitive↑, *Dose↝, *Dose↝,
7232- EGb 761,    Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial
- Trial, AD, NA
*cognitive↑, *toxicity↓,
7241- EGb 761,  ASA,    Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial
- Trial, Nor, NA
*Dose↝, *AntiAg∅,
2562- EGCG,    Green Tea Epigallocatechin 3-Gallate Reduced Platelet Aggregation and Improved Anticoagulant Proteins in Patients with Transfusion-Dependent β-Thalassemia: A Randomized Placebo-Controlled Clinical Trial
- Trial, NA, NA
AntiAg↑, other↝,
653- EGCG,    Phase 2 Trial of Daily, Oral Polyphenon E in Patients with Asymptomatic, Rai Stage 0-II Chronic Lymphocytic Leukemia(CLL)
- Trial, CLL, NA
ALC↓, Remission↑,
6790- EPA,    Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia
- Trial, Lung, NA
*Dose↝, Weight↑, cachexia↓, OS∅,
6792- EPA,    Effect of Eicosapentaenoic Acid on Body Composition and Inflammation Markers in Patients with Head and Neck Squamous Cell Cancer from a Public Hospital in Mexico
- Trial, HNSCC, NA
Dose↝, *IL1β↓, *IL6↓, *TNF-α↓, *IFN-γ↓, QoL↑,
5063- Ex,    A randomized controlled trial on the efficacy of supervised exercise training in reducing IGF-1 levels in breast cancer survivors of the Movis’ cohort
- Trial, BC, NA
IGF-1↓, IGFBP3↓,
4137- Ex,    The impact of exercise on patients with dementia
- Trial, AD, NA
*Strength↑, *QoL↑, *cognitive∅,
5234- Ex,    Intense Walking Exercise Affects Serum IGF-1 and IGFBP3
- Trial, Nor, NA
*IGF-1↓, *IGFBP3↓,
5235- Ex,    Effect of Low-Intensity Aerobic Exercise on Insulin-Like Growth Factor-I and Insulin-Like Growth Factor-Binding Proteins in Healthy Men
- Trial, Nor, NA
Insulin↓, IGF-1↓, IGFBP1↑, eff↑,
5230- Ex,    Effects of an acute maximal exercise bout on serum insulin-like growth factor-1 in adults with MDD
- Trial, Nor, NA
*IGF-1↑, Dose↝,
6870- FA,    Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial
- Trial, AD, NA
*Dose↝, *cognitive↑, *Hcy/homoC↓, *MMP9↓, *Risk↓,
6884- FA,    Effects of folic acid supplementation on cognitive function and Aβ-related biomarkers in mild cognitive impairment: a randomized controlled trial
- Trial, AD, NA
*cognitive↑, *Aβ↓, *BP↓, *SAM-e↓, *DNMT3A↑,

Showing Research Papers: 101 to 150 of 334
Prev Page 3 of 7 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 334

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1)

ROS↓, 1,   ROS↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics(tgid=3)

Insulin↓, 2,  

Core Metabolism/Glycolysis(tgid=4)

CYP3A4⇅, 1,   FAO↑, 1,   lactateProd↓, 1,   PDK1↓, 2,  

Transcription & Epigenetics(tgid=7)

other↑, 1,   other↝, 4,   other∅, 1,  

Autophagy & Lysosomes(tgid=9)

TumAuto↑, 1,  

Cell Cycle & Senescence(tgid=11)

cycD1/CCND1↓, 2,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12)

ALDH↓, 1,   IGF-1↓, 5,   IGF-1↑, 1,   IGFBP1↑, 2,   IGFBP3↓, 1,   IGFBP3↑, 1,   IGFR↓, 1,   TumCG↓, 1,   Wnt↓, 1,  

Migration(tgid=13)

AntiAg↑, 1,   MMP2↓, 1,   MMP9↓, 1,   TumCA↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   TumMeta↑, 1,   β-catenin/ZEB1↓, 1,  

Barriers & Transport(tgid=15)

P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

CD14↓, 1,   COX2↓, 1,   COX2∅, 1,   IFN-γ↑, 1,   IL1β∅, 1,   Imm↑, 3,   NF-kB↓, 1,   NK cell↑, 1,   TNF-α∅, 1,  

Drug Metabolism & Resistance(tgid=21)

ChemoSen↑, 2,   Dose↑, 1,   Dose↝, 8,   eff↑, 10,   eff↝, 1,   Half-Life↝, 2,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22)

ALC↓, 1,   BG↓, 1,  

Functional Outcomes(tgid=23)

AntiCan↑, 1,   cachexia↓, 1,   chemoPv↑, 2,   ChemoSideEff↓, 2,   NP/CIPN↑, 1,   OS↑, 5,   OS∅, 3,   QoL↑, 2,   QoL∅, 1,   Remission↑, 1,   Risk↓, 1,   Strength∅, 1,   toxicity↓, 2,   toxicity↑, 1,   toxicity↝, 2,   TumW↓, 1,   Weight↑, 1,   Weight∅, 1,  

Infection & Microbiome(tgid=24)

CD8+↑, 1,  
Total Targets: 70

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0)

NLR↓, 1,  

Redox & Oxidative Stress(tgid=1)

MDA↓, 1,   ROS↓, 1,   SAM-e↓, 1,   TAC↑, 1,  

Core Metabolism/Glycolysis(tgid=4)

DHA↑, 1,  

Transcription & Epigenetics(tgid=7)

AntiThr↑, 1,   other↝, 1,  

DNA Damage & Repair(tgid=10)

DNMT3A↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

IGF-1↓, 1,   IGF-1↑, 1,   IGFBP3↓, 1,  

Migration(tgid=13)

AntiAg↑, 2,   AntiAg∅, 1,   MMP9↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

CD14↑, 1,   CRP↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 2,   IL10↓, 1,   IL10↑, 1,   IL12↓, 1,   IL1β↓, 1,   IL4↑, 1,   IL6↓, 3,   Imm↑, 2,   Inflam↓, 3,   TNF-α↓, 1,   TNF-α↑, 2,  

Synaptic & Neurotransmission(tgid=18)

BrainVol∅, 1,  

Protein Aggregation(tgid=19)

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21)

BioAv↑, 1,   Dose↝, 7,   eff↑, 1,   eff↝, 2,  

Clinical Biomarkers(tgid=22)

BP↓, 3,   CRP↓, 1,   GutMicro↑, 1,   Hcy/homoC↓, 1,   IL6↓, 3,  

Functional Outcomes(tgid=23)

AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 1,   cognitive↑, 4,   cognitive∅, 3,   Obesity↓, 1,   QoL↑, 2,   Risk↓, 1,   Strength↑, 1,   toxicity?, 1,   toxicity↓, 3,  
Total Targets: 51

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page